01—Abstract
Summary
Summary of the 8-K filed February 26, 2026. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation (BSX) has executed significant financing agreements on February 26, 2026, including a $3.0 billiona revolving credit facility maturing in five years (2026 Revolving Credit Agreement) and a $2.0 billion 364-day revolving credit facility.
Additionally, the company entered into a $6.0 billionb term loan credit agreement (Term Loan Credit Agreement), featuring a $1.0 billion delayed draw term loan and a $5.0 billion delayed draw term loan, both set to mature 364 days after the closing of the Penumbra, Inc. acquisition. These new credit facilities collectively provide substantial liquidity and are crucial for funding the pending acquisition of Penumbra, Inc. The agreements include customary covenants and events of default, with a key financial covenant being a Maximum Leverage Ratio.
Notably, this ratio can temporarily increase to 4.75xc following a Qualified Acquisition, providing operational flexibility during integration periods. The company also terminated its prior 2021 revolving credit agreement in conjunction with these new arrangements.
02—Key points
Key Highlights
- Secured a new $3.0 billion, 5-year revolving credit facility (2026 Revolving Credit Agreement).
- Entered into a $2.0 billion, 364-day revolving credit facility, with its maturity potentially tied to the Penumbra acquisition closing.
- Established a $6.0 billion term loan credit facility to fund the acquisition of Penumbra, Inc., comprising a $1.0 billion and a $5.0 billion delayed draw tranche.
- The new credit agreements replace the prior 2021 revolving credit agreement.
- The agreements contain a Maximum Leverage Ratio covenant, with provisions for temporary increases following a Qualified Acquisition.
- Interest rates on borrowings are based on SOFR, Alternate Base Rate (ABR), or Eurocurrency rates, plus applicable margins tied to the Company's Credit Rating.
- The new financing provides significant liquidity to support the pending acquisition of Penumbra, Inc.
03—Questions
Frequently Asked Questions
What is the total amount of new credit facilities established by Boston Scientific?
Boston Scientific has established new credit facilities totaling $11.0 billion, comprising a $3.0 billion revolving credit agreement, a $2.0 billion 364-day revolving credit agreement, and a $6.0 billion term loan credit agreement.
What is the primary purpose of these new credit agreements?
The primary purpose of these new credit agreements, particularly the $6.0 billion term loan credit agreement, is to fund the pending acquisition of Penumbra, Inc. The revolving credit facilities also provide general corporate liquidity.
What is the maturity date of the new revolving credit facilities?
The 2026 Revolving Credit Agreement has a maturity date of February 26, 2031. The 364-Day Revolving Credit Agreement matures 364 days from the earlier of the availability of loans or the closing of the Penumbra acquisition.
Are there any significant financial covenants associated with these agreements?
Yes, a key financial covenant is the maintenance of a Maximum Leverage Ratio. This ratio is set at 3.75x, but can temporarily increase to 4.75x following a Qualified Acquisition, with step-downs over subsequent quarters.
04—Continue